BUDINSKÝ, Michal, Petr VYŠINSKÝ, Zdeněk ŘEHÁK and Jan ADAM. Zkušenosti s přípravou ⁶⁸Ga-PSMA-11 (Experience with the Preparation of Ga-68-PSMA-11). CHEMICKÉ LISTY. Praha: CHEMICKÉ LISTY, 2022, vol. 116, No 12, p. 746-750. ISSN 0009-2770. Available from: https://dx.doi.org/10.54779/chl20220746.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Zkušenosti s přípravou ⁶⁸Ga-PSMA-11
Name (in English) Experience with the Preparation of Ga-68-PSMA-11
Authors BUDINSKÝ, Michal (203 Czech Republic, belonging to the institution), Petr VYŠINSKÝ, Zdeněk ŘEHÁK (203 Czech Republic, belonging to the institution) and Jan ADAM (203 Czech Republic, guarantor, belonging to the institution).
Edition CHEMICKÉ LISTY, Praha, CHEMICKÉ LISTY, 2022, 0009-2770.
Other information
Original language Czech
Type of outcome Article in a journal
Field of Study 30104 Pharmacology and pharmacy
Country of publisher Czech Republic
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 0.600
RIV identification code RIV/00216224:14160/22:00128230
Organization unit Faculty of Pharmacy
Doi http://dx.doi.org/10.54779/chl20220746
UT WoS 000911169000005
Keywords (in Czech) ⁶⁸Ga-PSMA-11; karcinom prostaty; radiofarmacie; nukleární medicína
Keywords in English Ga-68-PSMA-11; prostate cancer; radiopharmacy; nuclear medicine
Tags rivok, ÚAF
Changed by Changed by: JUDr. Sabina Krejčiříková, učo 383857. Changed: 20/2/2023 16:41.
Abstract
Radiofarmakum 68Ga-PSMA-11 je off-label radiofarmakum pro diagnostiku karcinomu prostaty v rámci specifického léčebného programu. Z hlediska technologie přípravy je složitost přípravy 68Ga-PSMA-11 srovnatelná s přípravou běžných radiofarmak.
Abstract (in English)
The radiopharmaceutical 68Ga-PSMA-11 represents a radiopharmaceutical drug without marketing authorization for the prostate cancer diagnosis in a specific treatment program. In respect of the radiopharmaceutical technology, the difficultness of the preparation of 68Ga-PSMA-11 is comparable to that of conventional radiopharmaceuticals.
PrintDisplayed: 31/7/2024 22:32